{
  "source": "PA-Notification-Cinryze.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1018-13\nProgram Prior Authorization/Notification\nMedication Cinryze® (C1 esterase inhibitor, human)\nP&T Approval Date 11/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 7/2021,\n7/2022, 7/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nCinryze is a plasma-derived C1 esterase inhibitor (human) indicated for routine prophylaxis\nagainst angioedema attacks in adults, adolescents and pediatric patients (6 years of age and\nolder) with hereditary angioedema (HAE).1\n2. Coverage Criteriaa:\nA. Cinryze will be approved based on all of the following criteria:\n1. Diagnosis of hereditary angioedema (HAE)\n-AND-\n2. For prophylaxis against HAE attacks\n-AND-\n3. Not used in combination with other products indicated for prophylaxis against HAE attacks\n(e.g., Haegarda, Takhzyro, Orladeyo)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity and supply limits may be in place.\n4. References:\n1. Cinryze [package insert]. Lexington, MA: ViroPharma Biologics LLC; November 2024.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Cinryze (C1 esterase inhibitor,\nhuman)\nChange Control\n11/2013 New program.\n8/2014 Annual review. Added new criterion that concomitant acute therapies\ncannot be used. Decreased authorization from 60 months to 12 months.\nUpdated reference.\n8/2015 Annual review. No change.\n7/2016 Annual review with no changes to ",
    "erion that concomitant acute therapies\ncannot be used. Decreased authorization from 60 months to 12 months.\nUpdated reference.\n8/2015 Annual review. No change.\n7/2016 Annual review with no changes to the coverage criteria. Updated\nbackground and references.\n7/2017 Annual review with no changes to the coverage criteria. Updated\nreferences.\n7/2018 Annual review. Updated coverage criteria.\n7/2019 Annual review with no changes to coverage criteria. Updated\nbackground and references.\n7/2020 Annual review. Removed criteria for acute attacks. Updated\nbackground and references.\n7/2021 Annual review. Updated combination use criteria to include all\nprophylaxis agents. Updated references and background.\n7/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n7/2023 Annual review. Revised wording of criteria without change to clinical\nintent. Updated reference.\n3/2024 Annual review. No changes to coverage criteria.\n3/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}